Insight on Oncology in North America

The following industries match your search criteria:

Published within

« | 1 | » »|

Results are sorted by relevance. Click on heading titles to sort results by different field.

Type Product title / description Pub Price
Report
Report

Market and Product Forecasts: HER2-Negative/Hormone Receptor-Positive Breast Cancer - Patent expiries and novel drugs shape the market in the next decade

This report and accompanying deliverable provides forecasts for HER2-/HR+ breast cancer drugs in the seven major markets from 2011-20. Including in-depth analysis of the market in individual countries and molecule dynamics of the key therapies.

Published By Datamonitor
19 Jul 2012 $6400
Buy
Report
Report

Market and Product Forecasts: Rectal Cancer – Chemoradiation boosts cytotoxic use as new approvals add moderate value

This report and accompanying deliverable provide forecasts for rectal cancer drugs in the seven major markets over 2011–20, including in-depth analysis of the rectal cancer market in individual countries and molecule dynamics of the key therapies.

Published By Datamonitor
20 Feb 2012 $6400
Buy
Report
Report

Market and Product Forecasts: Colon Cancer - Older drugs remain dominant as new approvals struggle in saturated market

This report and accompanying deliverable provides forecasts for colon cancer drugs in the seven major markets from 2011-20. Including in-depth analysis of the colon cancer market in individual countries and molecule dynamics of the key therapies.

Published By Datamonitor
22 Dec 2011 $6400
Buy
Report
Report

Market and Product Forecasts: Prostate Cancer

Prostate cancer market growth is driven by uptake of recent approved therapies and launch of key pipeline candidates. Datamonitor forecasts continued expansion over the forecast period across the seven major markets at a CAGR of 8%.

Published By Datamonitor
21 Dec 2011 $6400
Buy
Report
Report

Product Profiles: Prostate Cancer – Recent approvals create competitive environment for new market entrants

Analysis of current market dynamics for the treatment of prostate cancer. The report assesses comparator therapies for prostate cancer, identifies key strategies for drug development, and analyzes commercial and clinical potential of pipeline drugs.

Published By Datamonitor
02 Sep 2011 $6400
Buy
Report
Report

R&D Trends Melanoma - Drug resistance provides an opportunity for drug developers

Review of key R&D trends in melanoma including; dynamics of the pipeline, comparator therapies, target product profile, trends in clinical trial design, innovative early-stage projects, and the future of melanoma treatment.

Published By Datamonitor
15 May 2012 $2800
Buy
Report
Report

R&D Trends: Colorectal Cancer - VEGF remains dominant but novel molecular targets are on the horizon

Review of key R&D trends in colorectal cancer including; dynamics of the pipeline, comparator therapies, target product profile, trends in clinical trial design, innovative early-stage projects, and the future of colorectal cancer treatment.

Published By Datamonitor
10 Jun 2011 $2800
Buy
Report
Report

Stakeholder Opinions: Hepatocellular cancer

Stakeholder Opinions: Hepatocellular Cancer discusses issues in the treatment of hepatocellular cancer, highlighting potential target populations for drug developers, treatment limitations and unmet needs, and an overview of the current pipeline.

Published By Datamonitor
01 Dec 2010 $2800
Buy

« | 1 | » »|

No help is available.